Sahlgrenska University Hospital
sahlgrenska.seLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
260
Active
67
Phase 3
5
Total enrollment
344,208
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| FOLFIRINOX or gemcitabine-nab-paclitaxel | — | — | — | — | — | 1 | |
| Histamine Dihydrochloride | — | — | — | — | — | 1 | |
| Interleukin-2 | — | — | — | — | — | 1 | |
| potassium binder | — | — | — | — | — | 1 | |
| 3 courses of chemotherapy; Blemocin, Etoposide and Platinum | — | — | — | — | — | 1 | |
| Volar to the MCP-joint | — | — | — | — | — | 1 | |
| Alteplase | — | — | — | — | — | 1 |
Next readouts
- 2027-04-01
- 2027-11-01
- 2028-05-01
- 2029-12-31
- 2031-03-25
- 2032-12-31
Top conditions
- Irritable Bowel Syndrome11
- Surgery10
- Rectal Cancer7
- Quality of Life6
- Diabetic Foot5
- Colorectal Cancer5
- Hip Fractures5
- Acute Kidney Injury4
Frequently asked questions about Sahlgrenska University Hospital
- How many clinical trials does Sahlgrenska University Hospital have on ClinicalTrials.gov?
- Sahlgrenska University Hospital is listed as the lead sponsor on 260 clinical trials in ClinicalTrials.gov, 67 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sahlgrenska University Hospital's trials are in Phase 3?
- 5 of Sahlgrenska University Hospital's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does Sahlgrenska University Hospital focus on?
- Sahlgrenska University Hospital's most-studied conditions on ClinicalTrials.gov are Irritable Bowel Syndrome, Surgery, Rectal Cancer, Quality of Life, Diabetic Foot.
- When are Sahlgrenska University Hospital's next clinical trial readouts?
- Sahlgrenska University Hospital has 6 upcoming primary-completion readouts tracked here; the soonest is “Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer”, expected around 2027-04-01.